Bleomycin Lung Injury
Bleomycin Lung Injury - Related Videos
06:52
Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
0 Views •
Cited by 13 •
2019
Here we present an effective method to investigate the antifibrotic activity of intravenously infused human mesenchymal stromal cells obtained from the whole umbilical cord following the induction of lung injury by an endotracheal injection of bleomycin in C57BL/6 mice. This protocol can be easily extended to the preclinical testing of other therapeutics.
05:45
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
0 Views •
2026
Here, we present a protocol to model pulmonary fibrosis in mice using aerosolized bleomycin delivered via the trachea. This optimized method enables uniform, quantitative, and precise delivery without surgical incision, enhancing the reproducibility and reliability of bleomycin-induced fibrosis.
08:58
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
0 Views •
2025
This protocol describes the development of a neonatal piglet model of acute lung injury that models early pathogenic events occurring in the preterm lung, including sub-adequate surfactant quantity, hyperoxia, high-pressure ventilation, and inflammation, to facilitate understanding of molecular triggers of bronchopulmonary dysplasia and enhance therapeutic translation.
07:55
Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice
0 Views •
Cited by 7 •
2011
A murine model for ventilator induced lung injury is an important tool to study an acute lung injury in vivo. Here, we report an easy applicable in situ model for acute lung injury using high-pressure mechanical ventilation to induce acute failure of the lung.
04:10
Non-Invasive Endotracheal Administration of Lipopolysaccharide to Induce Acute Lung Injury in Rodents
0 Views •
2025
In this study, a non-invasive endotracheal instillation technique is demonstrated to develop ALI in rats using a basic laryngoscope to ensure precise LPS delivery to the lungs. The LPS is instilled via an endotracheal tube using a laryngoscope. The magnitude of lung injury is evaluated at multiple time points.
FAQs
Bleomycin forms an iron-dependent complex that generates reactive oxygen species. These chemically reactive molecules damage cellular components, including DNA, and contribute to injury of alveolar epithelial cells. This mechanism connects drug exposure with the initial tissue damage that later activates inflammatory and repair processes, making iron-dependent oxidation central to understanding disease progression.
Alveolar epithelial cell injury provides an early tissue signal that can recruit and activate immune cells. The resulting inflammatory response releases cytokines and influences tissue remodeling. Because epithelial damage precedes these downstream events, studying these cells helps researchers connect direct drug toxicity with the transition from acute lung injury toward persistent structural changes.
Immune-cell recruitment and activation can amplify tissue injury through cytokine release while also shaping repair. These signals influence remodeling and collagen deposition, processes associated with fibrotic progression. In immunology research, examining this sequence helps clarify how innate inflammatory responses interact with damaged tissue and why repair may develop into chronic fibrosis rather than return to normal structure.
The acute phase centers on epithelial damage and inflammatory activation after reactive oxygen species cause cellular injury. Over time, continued cytokine signaling and tissue remodeling can promote collagen deposition and chronic fibrosis. This progression allows investigators to examine how an initial injury evolves into lasting structural change and to identify pathways that may influence each stage.
A study typically examines the sequence from bleomycin-associated epithelial damage through immune-cell recruitment, cytokine release, tissue remodeling, and collagen deposition. Researchers can then compare these biological outcomes across experimental conditions to determine how inflammatory pathways affect progression. This workflow links early injury mechanisms with later fibrotic changes without treating inflammation and repair as separate events.
The model provides a way to investigate interactions among damaged alveolar epithelium, innate immune responses, and pulmonary repair. Although the initiating insult is drug-associated, the resulting inflammatory and remodeling processes offer broader insight into how immune activation shapes tissue outcomes. It therefore supports mechanistic studies of inflammation, repair, and fibrosis within the lung.
Investigators can use the model to assess whether a candidate intervention changes the progression from inflammatory injury to collagen-rich fibrosis. Measurements focused on immune activation, cytokine release, tissue remodeling, or collagen deposition can reveal which stage is affected. This makes the system useful for connecting therapeutic effects with specific biological processes rather than evaluating fibrosis only as a final outcome.